1. Home
  2. VHI vs ADCT Comparison

VHI vs ADCT Comparison

Compare VHI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VHI

Valhi Inc.

HOLD

Current Price

$14.49

Market Cap

405.3M

Sector

Industrials

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.05

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHI
ADCT
Founded
1932
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
405.3M
431.2M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
VHI
ADCT
Price
$14.49
$1.05
Analyst Decision
Sell
Strong Buy
Analyst Count
1
4
Target Price
$12.00
$7.75
AVG Volume (30 Days)
13.4K
2.7M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
2.19%
N/A
EPS Growth
N/A
30.86
EPS
0.07
N/A
Revenue
$2,077,000,000.00
$81,357,000.00
Revenue This Year
$33.32
N/A
Revenue Next Year
N/A
$66.49
P/E Ratio
$207.00
N/A
Revenue Growth
N/A
14.85
52 Week Low
$11.44
$0.78
52 Week High
$20.00
$4.98

Technical Indicators

Market Signals
Indicator
VHI
ADCT
Relative Strength Index (RSI) 59.96 15.76
Support Level $13.64 N/A
Resistance Level $15.45 $4.77
Average True Range (ATR) 0.57 0.18
MACD 0.11 -0.19
Stochastic Oscillator 91.92 9.41

Price Performance

Historical Comparison
VHI
ADCT

About VHI Valhi Inc.

Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: